G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia-Reference-Cited by-同舟云学术

G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia

Published:2014-04-03 Issue:14 Volume:123 Page:2209-2219
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Lee Hee Kyu¹,Kim Hong Woo²,Lee In Yong²,Lee Jungmi²,Lee Jaekyoo²,Jung Dong Sik¹,Lee Sang Yeop¹,Park Sung Ho¹,Hwang Haejun¹,Choi Jang-Sik¹,Kim Jung-Ho¹,Kim Se Won¹,Kim Jung Keun¹,Cools Jan³,Koh Jong Sung²,Song Ho-Juhn²

Affiliation:

1. Oscotec Inc., Gyeonggi-do, Republic of Korea;

2. Genosco, Cambridge, MA; and

3. Center for the Biology of Disease, VIB, Leuven, Belgium

Abstract

Key Points A novel inhibitor G-749 is very potent against FLT3 kinase mutants including D835Y and ITD/F691L that confer resistance to PKC412 and AC220. G-749 shows several desirable characteristics to overcome other drug resistances conferred by patient plasma, FLT3 ligand, and stromal cells.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/14/2209/1375250/2209.pdf

Reference42 articles.

1. The role of FLT3 in haematopoietic malignancies.;Stirewalt;Nat Rev Cancer,2003

2. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.;Nakao;Leukemia,1996

3. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia.;Horiike;Leukemia,1997

4. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.;Yamamoto;Blood,2001

5. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia.;Kornblau;Blood,2006

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Annual review of PROTAC degraders as anticancer agents in 2022;European Journal of Medicinal Chemistry;2024-03

2. Update on Small Molecule Targeted Therapies for Acute Myeloid Leukemia;Current Treatment Options in Oncology;2023-05-17

3. Next-Generation FLT3 Inhibitors for the Treatment of FLT3-Positive AML;Pathogenesis and Treatment of Leukemia;2023

4. Small molecule inhibitors targeting the cancers;MedComm;2022-10-13

5. PROTACs: great opportunities for academia and industry (an update from 2020 to 2021);Signal Transduction and Targeted Therapy;2022-06-09